Meriden’s Protein Sciences said it has signed a deal that gives exclusive licensing rights for its flu vaccine to a Mexican company.
Under the agreement, Mexico City’s Laboratorios Liomont will have licensing rights to Flublok and Panblok, which are Protein Sciences’ season and pandemic flu vaccinations, respectively.
Liomont will pursue approval from Mexican regulators to sell the vaccines there. The agreement also gives the company manufacturing rights.
Exact terms of the deal were not disclosed, but Protein Sciences said it will receive “significant” license and milestone payments, as well as a double-digit cut of Liomont’s sales.
Flublok was approved by the U.S. Food & Drug Administration in early 2013. The vaccine was cleared in July for its second annual flu season, which typically begins in September.
